Show simple item record

dc.contributor.authorRamírez, Laura
dc.contributor.authorIborra, Salvador 
dc.contributor.authorCortés, Jimena
dc.contributor.authorBonay, Pedro
dc.contributor.authorAlonso, Carlos
dc.contributor.authorBarral-Netto, Manoel
dc.contributor.authorSoto, Manuel
dc.identifier.citationJ Biomed Biotechnol. 2010;2010:181690.es_ES
dc.description.abstractLeishmaniasis is an increasing public health problem and effective vaccines are not currently available. We have previously demonstrated that vaccination with ribosomal proteins extracts administered in combination of CpG oligodeoxynucleotides protects susceptible BALB/c mice against primary Leishmania major infection. Here, we evaluate the long-term immunity to secondary infection conferred by this vaccine. We show that vaccinated and infected BALB/c mice were able to control a secondary Leishmania major challenge, since no inflammation and very low number of parasites were observed in the site of reinfection. In addition, although an increment in the parasite burden was observed in the draining lymph nodes of the primary site of infection we did not detected inflammatory lesions at that site. Resistance against reinfection correlated to a predominant Th1 response against parasite antigens. Thus, cell cultures established from spleens and the draining lymph node of the secondary site of infection produced high levels of parasite specific IFN-gamma in the absence of IL-4 and IL-10 cytokine production. In addition, reinfected mice showed a high IgG2a/IgG1 ratio for anti-Leishmania antibodies. Our results suggest that ribosomal vaccine, which prevents pathology in a primary challenge, in combination with parasite persistence might be effective for long-term maintenance of immunity.es_ES
dc.description.sponsorshipThis study was supported by the Ministerio de Ciencia e Innovación and the Instituto de Salud Carlos III within the Network of Tropical Diseases Research (RICET RD06/0021/0008). Grants from Ministerio de Ciencia e Innovación (FIS/PI080101), from AECID (A/016407/08), from CYTED (207RT0308) and a Grant from Laboratorios LETI S.L. are acknowledged. An institutional grant from Fundación Ramón Areces is also acknowledged.es_ES
dc.publisherHindawi Publishing Corporationes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subject.meshAnimals es_ES
dc.subject.meshAntigens, Protozoan es_ES
dc.subject.meshCytokines es_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshFemale es_ES
dc.subject.meshLeishmania major es_ES
dc.subject.meshLeishmaniasis Vaccines es_ES
dc.subject.meshLeishmaniasis, Cutaneous es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Inbred BALB C es_ES
dc.subject.meshOligodeoxyribonucleotides es_ES
dc.subject.meshProtozoan Proteins es_ES
dc.subject.meshRibosomal Proteins es_ES
dc.titleBALB/c Mice Vaccinated withLeishmania majorRibosomal Proteins Extracts Combined with CpG Oligodeoxynucleotides Become Resistant to Disease Caused by a Secondary Parasite Challengees_ES
dc.rights.licenseAtribución-4.0 Internacional*
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos III-ISCIIIes_ES
dc.contributor.funderAgencia Española de Cooperación Internacional para el Desarrolloes_ES
dc.contributor.funderPrograma Iberoamericano de Ciencia y Tecnología para el Desarrollo (Cyted)es_ES
dc.contributor.funderLaboratorios LETIes_ES
dc.identifier.journalJournal of Biomedicine and Biotechnologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-4.0 Internacional
This item is licensed under a: Atribución-4.0 Internacional